Skip to main content
SpringerLink
Log in

PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Metabolic or molecular imaging with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has emerged as a powerful imaging modality for diagnosis, staging, and therapy monitoring of a variety of cancers. The accuracy of FDG-PET as an imaging tool for the primary staging of lymphoma suffers from the absence of a reference criterion to which all imaging modalities can be compared. For ethical reasons, pathological diagnosis is usually not possible for all of the lesions and abnormalities found. In this article, the current state of the art for staging of primary lymphoma is reviewed and the implications for staging and the impact on patient management discussed. Whole-body PET using FDG is superior to conventional staging, i.e., physical examination, laboratory tests, plain radiography, and CT, by 10–20%. The sensitivity of FDG-PET varies for different regions of the body and appears lowest for infradiaphragmatic disease involvement. Staging with metabolic imaging leads in 10–40% of patients to a change in clinical stage. Highly variable results have been reported on whether up- or downstaging of lymphoma with PET leads to changes in the therapeutic approach for primary lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23–47.

    PubMed  Google Scholar 

  2. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997; 27:94–106.

    CAS  PubMed  Google Scholar 

  3. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40:591–603.

    CAS  PubMed  Google Scholar 

  4. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32:686–691.

    CAS  PubMed  Google Scholar 

  5. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8:187–191.

    CAS  PubMed  Google Scholar 

  6. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33:325–329.

    CAS  PubMed  Google Scholar 

  7. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32:1211–1218.

    PubMed  Google Scholar 

  8. Front D, Israel O, Epelbaum R, et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990; 175:515–519.

    CAS  PubMed  Google Scholar 

  9. Delcambre C, Reman O, Henry-Amar M, et al. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 2000; 27:176–184.

    PubMed  Google Scholar 

  10. Bekerman C, Hoffer PB, Bitran JD. The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 1984; 14:296–323.

    CAS  PubMed  Google Scholar 

  11. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995; 25:60–71.

    CAS  PubMed  Google Scholar 

  12. Front D, Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med 1996; 37:530–532.

    CAS  PubMed  Google Scholar 

  13. Front D, Bar-Shalom R, Israel O. The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging. Semin Nucl Med 1997; 27:68–74.

    CAS  PubMed  Google Scholar 

  14. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28:288–292.

    Google Scholar 

  15. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose: correlation with CT. Radiology 1994; 190:111–116.

    CAS  PubMed  Google Scholar 

  16. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86:3522–3527.

    CAS  PubMed  Google Scholar 

  17. Rodriguez M. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma. Acta Radiol Suppl 1998; 417:1–36.

    CAS  PubMed  Google Scholar 

  18. Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 2001; 16:297–304.

    CAS  PubMed  Google Scholar 

  19. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12:825–830.

    Article  CAS  PubMed  Google Scholar 

  20. Jerusalem GH, Beguin YP. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 2002; 3:56–61.

    PubMed  Google Scholar 

  21. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94:879–888.

    Article  PubMed  Google Scholar 

  22. Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002; 16:337–345.

    PubMed  Google Scholar 

  23. Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E. Magnetic resonance imaging and67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. Magma 1996; 4(3–4):213–224.

    Google Scholar 

  24. Tomura N, Hirano H, Sashi R, et al. Comparison of MR imaging and CT in discriminating tumor infiltration of bone and bone marrow in the skull base. Comput Med Imaging Graph 1998; 22:41–51.

    Article  CAS  PubMed  Google Scholar 

  25. Wyttenbach R, Vock P, Tschappeler H. Cross-sectional imaging with CT and/or MRI of pediatric chest tumors. Eur Radiol 1998; 8:1040–1046.

    Article  CAS  PubMed  Google Scholar 

  26. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38:343–348.

    CAS  PubMed  Google Scholar 

  27. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795–800.

    CAS  PubMed  Google Scholar 

  28. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25:721–728.

    CAS  PubMed  Google Scholar 

  29. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206:475–481.

    CAS  PubMed  Google Scholar 

  30. Buchmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91:889–899.

    CAS  PubMed  Google Scholar 

  31. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603–609.

    CAS  PubMed  Google Scholar 

  32. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91:3340–3346.

    PubMed  Google Scholar 

  33. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-d glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11:1273–1279.

    CAS  PubMed  Google Scholar 

  34. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999; 40:1407–1413.

    CAS  PubMed  Google Scholar 

  35. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86:266–273.

    CAS  PubMed  Google Scholar 

  36. Rini JN, Manalili EY, Hoffman MA, et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002; 27:572–577.

    Article  PubMed  Google Scholar 

  37. Schöder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42:1139–1143.

    PubMed  Google Scholar 

  38. Jerusalem G, Warland V, Najjar F, et al. Whole-body18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20:13–20.

    CAS  PubMed  Google Scholar 

  39. Klose T, Leidl R, Buchmann I, Brambs HJ, Reske SN. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med 2000; 27:1457–1464.

    Article  CAS  PubMed  Google Scholar 

  40. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81:20–25.

    Article  CAS  PubMed  Google Scholar 

  41. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112:262–268.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ahmanson Biological Imaging Center, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, 10833 LeConte Avenue, Los Angeles, CA 90095-6948, USA

    Christiaan Schiepers, Jean-Emmanuel Filmont & Johannes Czernin

Authors
  1. Christiaan Schiepers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Emmanuel Filmont
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes Czernin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christiaan Schiepers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiepers, C., Filmont, JE. & Czernin, J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S82–S88 (2003). https://doi.org/10.1007/s00259-003-1165-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1165-6

Keywords

Search

Navigation